Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study
Introduction To compare the effects of ipragliflozin, a sodium-glucose transporter 2 inhibitor, with those of metformin on visceral fat (as well as muscles and bones) in Japanese elderly patients with type 2 diabetes (T2D), we conducted a sub-analysis of a prospective, multicenter, blinded-endpoint...
Gespeichert in:
| Veröffentlicht in: | Diabetes therapy 2021-01, Vol.12 (1), p.183-196 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 196 |
|---|---|
| container_issue | 1 |
| container_start_page | 183 |
| container_title | Diabetes therapy |
| container_volume | 12 |
| creator | Koshizaka, Masaya Ishikawa, Ko Ishibashi, Ryoichi Takahashi, Sho Sakamoto, Kenichi Yokoh, Hidetaka Baba, Yusuke Ide, Shintaro Ide, Kana Ishikawa, Takahiro Onishi, Shunichiro Kobayashi, Kazuki Takemoto, Minoru Horikoshi, Takuro Shimofusa, Ryota Maezawa, Yoshiro Yokote, Koutaro |
| description | Introduction
To compare the effects of ipragliflozin, a sodium-glucose transporter 2 inhibitor, with those of metformin on visceral fat (as well as muscles and bones) in Japanese elderly patients with type 2 diabetes (T2D), we conducted a sub-analysis of a prospective, multicenter, blinded-endpoint randomized-controlled study.
Methods
In total, 103 patients with T2D (body mass index ≥ 22 kg/m
2
; glycated hemoglobin, 7–10%) and being treated with sitagliptin (a dipeptidyl peptidase-4 inhibitor) were included and randomized to receive ipragliflozin or metformin. The primary outcome was the change in visceral fat area measured using computed tomography 24 weeks following treatment. The secondary outcomes included changes in subcutaneous and total fat area, muscle volume, bone density measured using computed tomography, handgrip strength, bone markers, plasma glucose, insulin, homeostasis model assessment (HOMA)2-beta, HOMA2-R, glycated hemoglobin, lipid panel, uric acid, blood pressure, adiponectin, and high-sensitivity C-reactive protein. All patients aged 65–74 years were selected for sub-analysis.
Results
The sub-analysis included 15 and 14 patients in the ipragliflozin and metformin groups, respectively. The patients’ backgrounds were well balanced. Visceral fat area reduction was greater in the ipragliflozin group than in the metformin group (− 10.58% vs. − 6.93%;
P
= 0.034). There were significant differences in the changes in bone absorption markers, uric acid, and total cholesterol levels between the groups.
Conclusion
Ipragliflozin significantly reduced the visceral fat area compared with metformin when added to sitagliptin in elderly patients with T2D. Long-term and large-scale studies are required to elucidate whether ipragliflozin is suitable for elderly patients.
Trial Registration
The study was registered at
https://www.umin.ac.jp/ctr/
(UMIN-ID: UMIN 000015170). |
| doi_str_mv | 10.1007/s13300-020-00949-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7843837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A651346867</galeid><sourcerecordid>A651346867</sourcerecordid><originalsourceid>FETCH-LOGICAL-c607t-adc7f9893e367aedd885fc0d080256a79d159a4c717efb420add99ad41fe15f63</originalsourceid><addsrcrecordid>eNp9kt1u1DAQhSMEolXpC3CBLHHDTYodJ07MBVK1tFCpCNQWbi1vPF5cOfbWTpDSB-F5mWXL0iJEfpTE853jzOgUxXNGjxil7evMOKe0pBXeVNaypI-KfdYJWQop2OPde8P3isOcrykeXErJ2NNiD6Wya0SzX_xYxGGtk8sxkGjJV5d7SNqTUz2SCzBTPzqsLGdytk565Z318dYFooMhH2G0MQ34hdeJN5D8TK7mNZCKvHN6CSNk8lmPDsKY35DLaVkeB-3n7PJmK00u0CUO7hZMuYhhTNF7MORynMz8rHhitc9wePc8KL6cnlwtPpTnn96fLY7Py17Qdiy16VsrO8mBi1aDMV3X2J4a2tGqEbqVhjVS133LWrDLuqLaGCm1qZkF1ljBD4q3W9_1tBzA9Pir2L1aJzfoNKuonXpYCe6bWsXvqu1q3vEWDV7dGaR4M0Ee1bAZofc6QJyyquqmZlQIWiH68i_0Ok4JJ4JUwyreiZbdo1bag3LBRty335iqY9EwXgvkkDr6B4WngcH1MYB1uP5AUG0FfYo5J7C7HhlVm0CpbaAUBkr9CpSiKHpxfzo7ye_4IMC3QMZSWEH609J_bH8Cu3zXDg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512386712</pqid></control><display><type>article</type><title>Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study</title><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Koshizaka, Masaya ; Ishikawa, Ko ; Ishibashi, Ryoichi ; Takahashi, Sho ; Sakamoto, Kenichi ; Yokoh, Hidetaka ; Baba, Yusuke ; Ide, Shintaro ; Ide, Kana ; Ishikawa, Takahiro ; Onishi, Shunichiro ; Kobayashi, Kazuki ; Takemoto, Minoru ; Horikoshi, Takuro ; Shimofusa, Ryota ; Maezawa, Yoshiro ; Yokote, Koutaro</creator><creatorcontrib>Koshizaka, Masaya ; Ishikawa, Ko ; Ishibashi, Ryoichi ; Takahashi, Sho ; Sakamoto, Kenichi ; Yokoh, Hidetaka ; Baba, Yusuke ; Ide, Shintaro ; Ide, Kana ; Ishikawa, Takahiro ; Onishi, Shunichiro ; Kobayashi, Kazuki ; Takemoto, Minoru ; Horikoshi, Takuro ; Shimofusa, Ryota ; Maezawa, Yoshiro ; Yokote, Koutaro</creatorcontrib><description>Introduction
To compare the effects of ipragliflozin, a sodium-glucose transporter 2 inhibitor, with those of metformin on visceral fat (as well as muscles and bones) in Japanese elderly patients with type 2 diabetes (T2D), we conducted a sub-analysis of a prospective, multicenter, blinded-endpoint randomized-controlled study.
Methods
In total, 103 patients with T2D (body mass index ≥ 22 kg/m
2
; glycated hemoglobin, 7–10%) and being treated with sitagliptin (a dipeptidyl peptidase-4 inhibitor) were included and randomized to receive ipragliflozin or metformin. The primary outcome was the change in visceral fat area measured using computed tomography 24 weeks following treatment. The secondary outcomes included changes in subcutaneous and total fat area, muscle volume, bone density measured using computed tomography, handgrip strength, bone markers, plasma glucose, insulin, homeostasis model assessment (HOMA)2-beta, HOMA2-R, glycated hemoglobin, lipid panel, uric acid, blood pressure, adiponectin, and high-sensitivity C-reactive protein. All patients aged 65–74 years were selected for sub-analysis.
Results
The sub-analysis included 15 and 14 patients in the ipragliflozin and metformin groups, respectively. The patients’ backgrounds were well balanced. Visceral fat area reduction was greater in the ipragliflozin group than in the metformin group (− 10.58% vs. − 6.93%;
P
= 0.034). There were significant differences in the changes in bone absorption markers, uric acid, and total cholesterol levels between the groups.
Conclusion
Ipragliflozin significantly reduced the visceral fat area compared with metformin when added to sitagliptin in elderly patients with T2D. Long-term and large-scale studies are required to elucidate whether ipragliflozin is suitable for elderly patients.
Trial Registration
The study was registered at
https://www.umin.ac.jp/ctr/
(UMIN-ID: UMIN 000015170).</description><identifier>ISSN: 1869-6953</identifier><identifier>EISSN: 1869-6961</identifier><identifier>DOI: 10.1007/s13300-020-00949-0</identifier><identifier>PMID: 33098565</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Adipose tissues ; Aged patients ; Antidiabetics ; Body weight ; Cardiology ; Diabetes ; Drug therapy ; Endocrinology ; Health aspects ; Hemoglobin ; Hypoglycemic agents ; Inhibitor drugs ; Insulin ; Internal Medicine ; Medicine ; Medicine & Public Health ; Original Research ; Patient outcomes ; Physiological aspects ; Uric acid</subject><ispartof>Diabetes therapy, 2021-01, Vol.12 (1), p.183-196</ispartof><rights>The Author(s) 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c607t-adc7f9893e367aedd885fc0d080256a79d159a4c717efb420add99ad41fe15f63</citedby><cites>FETCH-LOGICAL-c607t-adc7f9893e367aedd885fc0d080256a79d159a4c717efb420add99ad41fe15f63</cites><orcidid>0000-0001-7374-9993</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843837/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843837/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33098565$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koshizaka, Masaya</creatorcontrib><creatorcontrib>Ishikawa, Ko</creatorcontrib><creatorcontrib>Ishibashi, Ryoichi</creatorcontrib><creatorcontrib>Takahashi, Sho</creatorcontrib><creatorcontrib>Sakamoto, Kenichi</creatorcontrib><creatorcontrib>Yokoh, Hidetaka</creatorcontrib><creatorcontrib>Baba, Yusuke</creatorcontrib><creatorcontrib>Ide, Shintaro</creatorcontrib><creatorcontrib>Ide, Kana</creatorcontrib><creatorcontrib>Ishikawa, Takahiro</creatorcontrib><creatorcontrib>Onishi, Shunichiro</creatorcontrib><creatorcontrib>Kobayashi, Kazuki</creatorcontrib><creatorcontrib>Takemoto, Minoru</creatorcontrib><creatorcontrib>Horikoshi, Takuro</creatorcontrib><creatorcontrib>Shimofusa, Ryota</creatorcontrib><creatorcontrib>Maezawa, Yoshiro</creatorcontrib><creatorcontrib>Yokote, Koutaro</creatorcontrib><title>Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study</title><title>Diabetes therapy</title><addtitle>Diabetes Ther</addtitle><addtitle>Diabetes Ther</addtitle><description>Introduction
To compare the effects of ipragliflozin, a sodium-glucose transporter 2 inhibitor, with those of metformin on visceral fat (as well as muscles and bones) in Japanese elderly patients with type 2 diabetes (T2D), we conducted a sub-analysis of a prospective, multicenter, blinded-endpoint randomized-controlled study.
Methods
In total, 103 patients with T2D (body mass index ≥ 22 kg/m
2
; glycated hemoglobin, 7–10%) and being treated with sitagliptin (a dipeptidyl peptidase-4 inhibitor) were included and randomized to receive ipragliflozin or metformin. The primary outcome was the change in visceral fat area measured using computed tomography 24 weeks following treatment. The secondary outcomes included changes in subcutaneous and total fat area, muscle volume, bone density measured using computed tomography, handgrip strength, bone markers, plasma glucose, insulin, homeostasis model assessment (HOMA)2-beta, HOMA2-R, glycated hemoglobin, lipid panel, uric acid, blood pressure, adiponectin, and high-sensitivity C-reactive protein. All patients aged 65–74 years were selected for sub-analysis.
Results
The sub-analysis included 15 and 14 patients in the ipragliflozin and metformin groups, respectively. The patients’ backgrounds were well balanced. Visceral fat area reduction was greater in the ipragliflozin group than in the metformin group (− 10.58% vs. − 6.93%;
P
= 0.034). There were significant differences in the changes in bone absorption markers, uric acid, and total cholesterol levels between the groups.
Conclusion
Ipragliflozin significantly reduced the visceral fat area compared with metformin when added to sitagliptin in elderly patients with T2D. Long-term and large-scale studies are required to elucidate whether ipragliflozin is suitable for elderly patients.
Trial Registration
The study was registered at
https://www.umin.ac.jp/ctr/
(UMIN-ID: UMIN 000015170).</description><subject>Adipose tissues</subject><subject>Aged patients</subject><subject>Antidiabetics</subject><subject>Body weight</subject><subject>Cardiology</subject><subject>Diabetes</subject><subject>Drug therapy</subject><subject>Endocrinology</subject><subject>Health aspects</subject><subject>Hemoglobin</subject><subject>Hypoglycemic agents</subject><subject>Inhibitor drugs</subject><subject>Insulin</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Research</subject><subject>Patient outcomes</subject><subject>Physiological aspects</subject><subject>Uric acid</subject><issn>1869-6953</issn><issn>1869-6961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9kt1u1DAQhSMEolXpC3CBLHHDTYodJ07MBVK1tFCpCNQWbi1vPF5cOfbWTpDSB-F5mWXL0iJEfpTE853jzOgUxXNGjxil7evMOKe0pBXeVNaypI-KfdYJWQop2OPde8P3isOcrykeXErJ2NNiD6Wya0SzX_xYxGGtk8sxkGjJV5d7SNqTUz2SCzBTPzqsLGdytk565Z318dYFooMhH2G0MQ34hdeJN5D8TK7mNZCKvHN6CSNk8lmPDsKY35DLaVkeB-3n7PJmK00u0CUO7hZMuYhhTNF7MORynMz8rHhitc9wePc8KL6cnlwtPpTnn96fLY7Py17Qdiy16VsrO8mBi1aDMV3X2J4a2tGqEbqVhjVS133LWrDLuqLaGCm1qZkF1ljBD4q3W9_1tBzA9Pir2L1aJzfoNKuonXpYCe6bWsXvqu1q3vEWDV7dGaR4M0Ee1bAZofc6QJyyquqmZlQIWiH68i_0Ok4JJ4JUwyreiZbdo1bag3LBRty335iqY9EwXgvkkDr6B4WngcH1MYB1uP5AUG0FfYo5J7C7HhlVm0CpbaAUBkr9CpSiKHpxfzo7ye_4IMC3QMZSWEH609J_bH8Cu3zXDg</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Koshizaka, Masaya</creator><creator>Ishikawa, Ko</creator><creator>Ishibashi, Ryoichi</creator><creator>Takahashi, Sho</creator><creator>Sakamoto, Kenichi</creator><creator>Yokoh, Hidetaka</creator><creator>Baba, Yusuke</creator><creator>Ide, Shintaro</creator><creator>Ide, Kana</creator><creator>Ishikawa, Takahiro</creator><creator>Onishi, Shunichiro</creator><creator>Kobayashi, Kazuki</creator><creator>Takemoto, Minoru</creator><creator>Horikoshi, Takuro</creator><creator>Shimofusa, Ryota</creator><creator>Maezawa, Yoshiro</creator><creator>Yokote, Koutaro</creator><general>Springer Healthcare</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7374-9993</orcidid></search><sort><creationdate>20210101</creationdate><title>Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study</title><author>Koshizaka, Masaya ; Ishikawa, Ko ; Ishibashi, Ryoichi ; Takahashi, Sho ; Sakamoto, Kenichi ; Yokoh, Hidetaka ; Baba, Yusuke ; Ide, Shintaro ; Ide, Kana ; Ishikawa, Takahiro ; Onishi, Shunichiro ; Kobayashi, Kazuki ; Takemoto, Minoru ; Horikoshi, Takuro ; Shimofusa, Ryota ; Maezawa, Yoshiro ; Yokote, Koutaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c607t-adc7f9893e367aedd885fc0d080256a79d159a4c717efb420add99ad41fe15f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adipose tissues</topic><topic>Aged patients</topic><topic>Antidiabetics</topic><topic>Body weight</topic><topic>Cardiology</topic><topic>Diabetes</topic><topic>Drug therapy</topic><topic>Endocrinology</topic><topic>Health aspects</topic><topic>Hemoglobin</topic><topic>Hypoglycemic agents</topic><topic>Inhibitor drugs</topic><topic>Insulin</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Research</topic><topic>Patient outcomes</topic><topic>Physiological aspects</topic><topic>Uric acid</topic><toplevel>online_resources</toplevel><creatorcontrib>Koshizaka, Masaya</creatorcontrib><creatorcontrib>Ishikawa, Ko</creatorcontrib><creatorcontrib>Ishibashi, Ryoichi</creatorcontrib><creatorcontrib>Takahashi, Sho</creatorcontrib><creatorcontrib>Sakamoto, Kenichi</creatorcontrib><creatorcontrib>Yokoh, Hidetaka</creatorcontrib><creatorcontrib>Baba, Yusuke</creatorcontrib><creatorcontrib>Ide, Shintaro</creatorcontrib><creatorcontrib>Ide, Kana</creatorcontrib><creatorcontrib>Ishikawa, Takahiro</creatorcontrib><creatorcontrib>Onishi, Shunichiro</creatorcontrib><creatorcontrib>Kobayashi, Kazuki</creatorcontrib><creatorcontrib>Takemoto, Minoru</creatorcontrib><creatorcontrib>Horikoshi, Takuro</creatorcontrib><creatorcontrib>Shimofusa, Ryota</creatorcontrib><creatorcontrib>Maezawa, Yoshiro</creatorcontrib><creatorcontrib>Yokote, Koutaro</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diabetes therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koshizaka, Masaya</au><au>Ishikawa, Ko</au><au>Ishibashi, Ryoichi</au><au>Takahashi, Sho</au><au>Sakamoto, Kenichi</au><au>Yokoh, Hidetaka</au><au>Baba, Yusuke</au><au>Ide, Shintaro</au><au>Ide, Kana</au><au>Ishikawa, Takahiro</au><au>Onishi, Shunichiro</au><au>Kobayashi, Kazuki</au><au>Takemoto, Minoru</au><au>Horikoshi, Takuro</au><au>Shimofusa, Ryota</au><au>Maezawa, Yoshiro</au><au>Yokote, Koutaro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study</atitle><jtitle>Diabetes therapy</jtitle><stitle>Diabetes Ther</stitle><addtitle>Diabetes Ther</addtitle><date>2021-01-01</date><risdate>2021</risdate><volume>12</volume><issue>1</issue><spage>183</spage><epage>196</epage><pages>183-196</pages><issn>1869-6953</issn><eissn>1869-6961</eissn><abstract>Introduction
To compare the effects of ipragliflozin, a sodium-glucose transporter 2 inhibitor, with those of metformin on visceral fat (as well as muscles and bones) in Japanese elderly patients with type 2 diabetes (T2D), we conducted a sub-analysis of a prospective, multicenter, blinded-endpoint randomized-controlled study.
Methods
In total, 103 patients with T2D (body mass index ≥ 22 kg/m
2
; glycated hemoglobin, 7–10%) and being treated with sitagliptin (a dipeptidyl peptidase-4 inhibitor) were included and randomized to receive ipragliflozin or metformin. The primary outcome was the change in visceral fat area measured using computed tomography 24 weeks following treatment. The secondary outcomes included changes in subcutaneous and total fat area, muscle volume, bone density measured using computed tomography, handgrip strength, bone markers, plasma glucose, insulin, homeostasis model assessment (HOMA)2-beta, HOMA2-R, glycated hemoglobin, lipid panel, uric acid, blood pressure, adiponectin, and high-sensitivity C-reactive protein. All patients aged 65–74 years were selected for sub-analysis.
Results
The sub-analysis included 15 and 14 patients in the ipragliflozin and metformin groups, respectively. The patients’ backgrounds were well balanced. Visceral fat area reduction was greater in the ipragliflozin group than in the metformin group (− 10.58% vs. − 6.93%;
P
= 0.034). There were significant differences in the changes in bone absorption markers, uric acid, and total cholesterol levels between the groups.
Conclusion
Ipragliflozin significantly reduced the visceral fat area compared with metformin when added to sitagliptin in elderly patients with T2D. Long-term and large-scale studies are required to elucidate whether ipragliflozin is suitable for elderly patients.
Trial Registration
The study was registered at
https://www.umin.ac.jp/ctr/
(UMIN-ID: UMIN 000015170).</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>33098565</pmid><doi>10.1007/s13300-020-00949-0</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-7374-9993</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1869-6953 |
| ispartof | Diabetes therapy, 2021-01, Vol.12 (1), p.183-196 |
| issn | 1869-6953 1869-6961 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7843837 |
| source | DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adipose tissues Aged patients Antidiabetics Body weight Cardiology Diabetes Drug therapy Endocrinology Health aspects Hemoglobin Hypoglycemic agents Inhibitor drugs Insulin Internal Medicine Medicine Medicine & Public Health Original Research Patient outcomes Physiological aspects Uric acid |
| title | Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A05%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Visceral%20Fat%20Reduction%20by%20Ipragliflozin%20and%20Metformin%20in%20Elderly%20Type%202%20Diabetes%20Patients:%20Sub-Analysis%20of%20a%20Randomized-Controlled%20Study&rft.jtitle=Diabetes%20therapy&rft.au=Koshizaka,%20Masaya&rft.date=2021-01-01&rft.volume=12&rft.issue=1&rft.spage=183&rft.epage=196&rft.pages=183-196&rft.issn=1869-6953&rft.eissn=1869-6961&rft_id=info:doi/10.1007/s13300-020-00949-0&rft_dat=%3Cgale_pubme%3EA651346867%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512386712&rft_id=info:pmid/33098565&rft_galeid=A651346867&rfr_iscdi=true |